drugset / Trial / NCT07538635

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

NCT07538635

Phase 2 Recruiting 20 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.

Timeline

Start
2026-04-20
Primary completion
2028-02-29
Completion
2028-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Axicabtagene Ciloleucel Cell therapy 2e+06 cells/kg Intravenous